CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
C	RAD51D	R186*	Predisposing	N/A		Breast Cancer		Baker et al., 2015
D	ALDH1A2	Underexpression	Predictive	Supports	Sensitivity/Response	Head And Neck Squamous Cell Carcinoma	Tretinoin	Seidensaal et al., 2015
C	EML4::ALK	Fusion	Predictive	Supports	Resistance	Lung Acinar Adenocarcinoma	Erlotinib	Tanaka et al., 2012
C	KRAS	Q22*	Predictive	Supports	Resistance	Colon Mucinous Adenocarcinoma	Panitumumab	Palmirotta et al., 2009
B	FLT3	ITD	Predictive	Supports	Resistance	Acute Myeloid Leukemia	Selumetinib	Jain et al., 2014
D	TBK1	Overexpression	Predictive	Supports	Sensitivity/Response	Melanoma	AZ909,Selumetinib	Vu et al., 2014
B	KRAS	G12C	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Docetaxel,Selumetinib	Jänne et al., 2015
B	TP53	Deleterious Mutation	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Adjuvant Chemotherapy	Ma et al., 2016
B	CDKN2A	p16 Expression	Predictive	Supports	Resistance	Head And Neck Squamous Cell Carcinoma	Afatinib	Machiels et al., 2015
B	MMP2	SERUM LEVELS	Predictive	Supports	Sensitivity/Response	Brain Glioma	Bevacizumab	Tabouret et al., 2014
B	ACTA1	EXPRESSION	Prognostic	Supports	Poor Outcome	Lung Adenocarcinoma		Hoda et al., 2016
B	HSPH1	NUCLEAR EXPRESSION	Prognostic	Supports	Poor Outcome	Gastric Adenocarcinoma		Kimura et al., 2016
B	HSPH1	T17 DELETION	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Fluorouracil,Oxaliplatin	Collura et al., 2014
B	PIM1	NUCLEAR EXPRESSION	Prognostic	Supports	Poor Outcome	Lung Non-small Cell Carcinoma		Jiang et al., 2016
B	MDM2	SNP309	Prognostic	Supports	Poor Outcome	Head And Neck Cancer		Vivenza et al., 2016
B	TP53	Deleterious Mutation	Predictive	Supports	Sensitivity/Response	Sarcoma	Pazopanib	Koehler et al., 2016
D	PIK3CA	E545K	Predictive	Supports	Resistance	Lung Adenocarcinoma	Gefitinib	Engelman et al., 2006
C	EML4::ALK	e20::e20	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Crizotinib	Kwak et al., 2010
D	EML4::ALK	e6::e20	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	ALK Inhibitor TAE684	McDermott et al., 2008
D	EML4::ALK	e6::e20	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	ALK Inhibitor TAE684	Koivunen et al., 2008
D	EML4::ALK	e20::e20	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Crizotinib	Heuckmann et al., 2012
D	EML4::ALK	e6::e20	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Crizotinib	Heuckmann et al., 2012
C	v::ALK	Fusion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Retaspimycin Hydrochloride	Sequist et al., 2010
D	EML4::ALK	e20::e20	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Crizotinib,Alvespimycin	Heuckmann et al., 2012
D	EML4::ALK	e6::e20	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Alvespimycin	Heuckmann et al., 2012
D	EML4::ALK	Fusion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Alvespimycin,Crizotinib	Heuckmann et al., 2012
E	TP53	P47S	Predictive	Supports	Resistance	Cancer	Cisplatin	Jennis et al., 2016
D	GNAQ	Mutation	Predictive	Supports	Sensitivity/Response	Uveal Melanoma	JQ1	Ambrosini et al., 2015
B	KRAS	Mutation	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Trametinib	Infante et al., 2012
B	NRAS	Mutation	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Trametinib,Docetaxel	Coupe et al., 2015
B	NRAS	Q61	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Binimetinib	Ascierto et al., 2013
B	NRAS	Mutation	Predictive	Does Not Support	Sensitivity/Response	Melanoma	Trametinib	Falchook et al., 2012
C	GNA11	Mutation	Predictive	Supports	Sensitivity/Response	Uveal Melanoma	Trametinib	Falchook et al., 2012
B	GNAQ	Mutation	Predictive	Supports	Sensitivity/Response	Uveal Melanoma	Trametinib	Falchook et al., 2012
C	GNAQ	Q209	Predictive	Supports	Sensitivity/Response	Uveal Melanoma	Refametinib	Weekes et al., 2013
E	BAP1	Loss	Predictive	Supports	Sensitivity/Response	Malignant Mesothelioma	Vorinostat,Mocetinostat	Sacco et al., 2015
E	FGFR1	N546K	Predictive	Supports	Sensitivity/Response	Ewing Sarcoma Of Bone	Ponatinib	Agelopoulos et al., 2015
D	ROS1	L2026M AND CD74::ROS1 Fusion	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Crizotinib	Zou et al., 2015
D	ROS1	G2032R AND CD74::ROS1 Fusion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Foretinib	Song et al., 2015
D	ROS1	L2026M AND CD74::ROS1 Fusion	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Crizotinib	Song et al., 2015
D	ROS1	L2026M AND CD74::ROS1 Fusion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Foretinib	Song et al., 2015
D	ROS1	G2101A AND CD74::ROS1 Fusion	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Crizotinib	Song et al., 2015
D	ROS1	G2101A AND CD74::ROS1 Fusion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Foretinib	Song et al., 2015
C	v::ALK	Fusion	Predictive	Supports	Sensitivity/Response	Diffuse Large B-cell Lymphoma	Crizotinib	Wass et al., 2014
C	ALK	R1275Q	Predictive	Supports	Sensitivity/Response	Neuroblastoma	Crizotinib	Mossé et al., 2013
C	ALK	R1275Q	Predictive	Supports	Sensitivity/Response	Neuroblastoma	Crizotinib	Mossé et al., 2013
D	EML4::ALK	Fusion AND ALK V1180L	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Crizotinib	Katayama et al., 2014
D	EML4::ALK	Fusion AND ALK V1180L	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Brigatinib	Katayama et al., 2014
B	ATM	Underexpression	Prognostic	Supports	Poor Outcome	Pancreatic Cancer		Kamphues et al., 2015
E	v::ROS1	Fusion	Predictive	Supports	Sensitivity/Response	Colorectal Adenocarcinoma	Crizotinib	Aisner et al., 2014

Page 70 of 96

Previous Next